RUA Life Sciences is a holding company for a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM).
Investing in Growth
While RUA Life Sciences’ FY 2021 results echoed some of the challenges from last year’s pandemic,...
Read moreMinor bump in the road to 510k submission
RUA have released a precautionary announcement noting a minor delay to the 510k submission for its...
Read moreDirection of travel intact
Ahead of its FY 2021 results in July, RUA Life Sciences’ trading update included its first year...
Read moreFundraising completed
On 30th December 2020, RUA reported that shareholders had approved resolutions regarding the...
Read moreChristmas comes early – Fundraising and Interims
RUA have announced a Placing and Open Offer conditional on shareholder approval at a General...
Read moreHeart valve progress
RUA have announced an earlier than expected update on the testing of its Elast-Eon-coated...
Read more‘A fully formed medical device manufacturer’
RUA Life Sciences announced its trading update for the six months to 30 September 2020. The global...
Read more
Graft progress reflected in new valuation
RUA Life Sciences has announced that their graft products have moved into the final long-term...
Read moreCEO & Chairman Interview - Positive AGM statement
Chairman, Bill Brown and CEO, David Richmond discuss a year of substantial change and progress for...
Read morePositive AGM statement
RUA have provided a recent flurry of positive news, including an update on RUA Vascular division’s...
Read more- Prev
- 1 of 2 pages
- Next
Register to be first
Get research on the companies that interest you straight to your inbox
